Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Harrison, Claire; Nangalia, Jyoti; H. Boucher, Rebecca; Jackson, Aimee; Yap, Christina; O’Sullivan, Jennifer; Fox, Sonia; Ailts, Isaak; C. Dueck, Amylou; L. Geyer, Holly; A. Mesa, Ruben; G. Dunn, William; Nadezhdin, Eugene; Curto‐García, Natalia; Green, Anna; S. Wilkins, Bridget; Coppell, Jason; Laurie, John; Garg, Mamta; Ewing, Joanne; Knapper, Steven; Crowe, Josephine; Chen, Frederick; Koutsavlis, Ioannis; L. Godfrey, Anna; Arami, Siamak; W. Drummond, Mark; Byrne, Jenny; Clark, Fiona; Mead‐Harvey, Carolyn; Joanna Baxter, E.; Frances McMullin, Mary; J. Mead, Adam

doi:10.1200/jco.22.01935

Public

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Published in Journal of Clinical Oncology • May 1, 2023

Authors:

Claire Harrison

Jyoti Nangalia

Rebecca H. Boucher

Abstract

PURPOSE Polycythemia vera (PV) is characterized by JAK/STAT activation, thrombotic/hemorrhagic events, systemic symptoms, and disease transformation. In high-risk PV, ruxolitinib controls blood counts and improves symptoms. PATIENTS AND METHODS MAJIC-PV is a randomized phase II trial of ruxolitinib ...

Subject

Ruxolitinib

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!